Borderline pathology of a core needle biopsy for breast cancer seems to mean that its in a grey zone between benign diagnosis and a cancer diagnoses.
In an issue of the British Journal of Cancer it states that one-third of breast core needle biopsy (CNB) specimens with borderline pathology prove to be malignant.
Dr. Nehmat Houssami and Dr. Stefano said in an interview with Reuters Health "We want physicians to keep in mind that a CNB diagnosis of a borderline lesion is not 'negative' for cancer, and on the contrary, it is flagged that further management/treatment step is needed."
The article also states that the information to the patient should be balanced. Yes, this could be breast cancer but to reassure a bit ( I don't know if this would actually make me less anxious) but approximately one in three will actually be malignant and the other two will prove to be benign.
Take home message: Read you pathology report, get help understanding your pathology reports and make sure if the results need to be investigated further that you push for it.
And oh yes, I have been in that wonderful position pictured -- wasn't all that bad. That time it came back benign!
Researchers have found that when cells become cancerous, they become 100 times more likely to genetically mutate than non-cancerous cells. This explains why tumor cells have so many mutations. Good news on the research front. But bad news on the treatment front -- because therapies that target a certain gene may be largely ineffective in controlling cancer.
Kidney transplants can save lives. They can also increase the risk of developing a variety of cancers, according to Australian researchers who report a risk 300 percent higher than in the general population.
According to a report in the August 15th Cancer Research stem cell-like glioma cells, taken from 
Studies presented at the American Urilogical Association expand the role of the NMP22 Bladder Chek Test. It improves bladder cancer detection to 99 percent, aiding the earlier detection of cancer and is reported to indicate the likelihood of life threatening bladder malignancy. It is recommended for use in screening high risk populations for bladder cancer to save lives and reduce expense. It is also four times more effective than the conventional laboratory urine test in detecting recurrent bladder cancer.
